Novartis Gene Therapies
Illinois
United States
107 articles about Novartis Gene Therapies
-
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
5/5/2019
Interim data reported for the first time from SPR1NT in pre-symptomatic SMA showed age-appropriate motor milestone achievement
-
According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don't stop looking. You never know what may come your way!
-
Just as Novartis and AveXis’ gene therapy, Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy (SMA) is progressing toward approval, a second patient death was reported.
-
1Q2019 Life Science Growth Announcements
4/18/2019
In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry. -
AveXis, a Novartis company, announced interim data from its Phase III STR1VE clinical trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.
-
AveXis data reinforce effectiveness of Zolgensma® in treating spinal muscular atrophy (SMA) Type 1
4/16/2019
• Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial • First-in-human biodistribution data show transduction in intended CNS targets and widespread SMN expression comparable to tissue from unaffected control • More than 150 patients treated with Zolgensma, only 5% of screened patients up to 5 years old excluded due to AAV9 antibody titers greater than 1:50
-
The Novartis subsidiary said it plans to offer jobs to the 150 employees currently working at the Colorado facility and add additional headcount there in the future.
-
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
4/1/2019
Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy
-
Anchored by Raleigh, Durham and the Research Triangle Park region, BioSpace’s Bio NC Hotbed is one of the faster-growing areas for biopharma in the U.S.
-
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
-
According to a recent BioSpace survey, 70% of life science employers indicated their company anticipates an increase in the number of open positions during 2019. So if you are on the job hunt, keep your eye out for new positions posted throughout the year!
-
It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.
-
On Monday, N.C. Gov. Roy Cooper announced the expansion to the company’s Durham facility that was first announced in May 2018. It's expected to provide up to 200 additional jobs.
-
According to a BioSpace Community Survey, almost 70% of life sciences professionals plan to look for a new job in the next 12 months. Don't delay, accelerate your job search and check out top companies who are looking for quality candidates in 2019!
-
“Think of it as an installment plan that’s then tied to how well the therapy works,” Mark Trusheim, strategic director of the MIT Center for Biomedical Innovation’s NEWDIGS program, told Business Insider. “This would be a car loan but you’ve still got to see if the car is going to work.”
-
It's a new year! Is one of your New Year's resolutions to find a new job? Jump start your job search now and check out top companies who are looking for quality candidates in 2019!
-
Using a calculation, ICER believes the Novartis gene therapy for Spinal Muscular Atrophy will be more cost effective than Biogen's Spinraza.
-
Winter and the Holidays are right around the corner, but don't stop your job search! Check out the top companies who are looking for candidates like you right now!
-
Days after Novartis axed one-fifth of its research programs, the Swiss pharma giant said it intends to seek regulatory approval for 60 new treatments between 2019 and 2021.
-
Top 12 Life Science Companies Hiring Now
11/2/2018
Fall is in full swing, but not falling short of jobs. Check out the top companies who are looking for candidates like you right now!